ScreenPoint Transpara vs TeraRecon

openFDA lists eight Transpara 510(k)s from K181704 on November 21, 2018 to K260898 on August 14, 2026, and Transpara Density (K232096) covers breast density. A group reading 2D and 3D mammograms, the setting of the MASAI screening trial, is the buyer, and the vendor calls the product vendor agnostic across FFDM and DBT systems. EU-Startups reported in April 2026 that ScreenPoint raised EUR 13.6M, EUR 11.9M of it equity from Insight Partners, Siemens Healthineers and others plus EUR 1.7M in grants.

TeraRecon sits in another department, with algorithms that run on CT and MR. DETECT runs imaging biomarkers during review, with modules for coronary plaque on cardiac CT, liver density on CT, and vertebral compression fractures and bone mineral density on chest or abdominal CT. TeraRecon Cardiac.Chambers.MR (K241312, November 5, 2024) segments cardiac chambers on adult MR, and Cardiovascular.Calcification.CT (K250288, October 23, 2025) outputs a calcium scoring mask for GE or Siemens CT only. A hospital cardiac imaging service is the buyer.